Financial Survey: Lexicon Pharmaceuticals (NASDAQ:LXRX) vs. Swedish Orphan Biovitrum (OTCMKTS:BIOVF)

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Swedish Orphan Biovitrum (OTCMKTS:BIOVF) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Lexicon Pharmaceuticals and Swedish Orphan Biovitrum’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%
Swedish Orphan Biovitrum	4.74%	17.72%	9.27%

Institutional and Insider Ownership

74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Lexicon Pharmaceuticals and Swedish Orphan Biovitrum”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$49.80 million	18.41	-$50.34 million	($0.15)	-13.73
Swedish Orphan Biovitrum	$2.89 billion	5.94	$48.85 million	$0.45	106.95

Swedish Orphan Biovitrum has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Swedish Orphan Biovitrum, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Lexicon Pharmaceuticals and Swedish Orphan Biovitrum, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1	1	2	0	2.25
Swedish Orphan Biovitrum	0	3	4	0	2.57

Lexicon Pharmaceuticals currently has a consensus price target of $4.55, indicating a potential upside of 120.87%. Given Lexicon Pharmaceuticals’ higher probable upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Swedish Orphan Biovitrum.

Risk & Volatility

Lexicon Pharmaceuticals has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500. Comparatively, Swedish Orphan Biovitrum has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500.

Summary

Swedish Orphan Biovitrum beats Lexicon Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.